Thus far the company has yielded some pretty impressive results with treating skin cancer. Though the company may be small, it most certainly is mighty. The investment community is catching drift of the potential here and I am on board too!
Lion Biotechnologies has a unique methodology in that tumor-infiltrating lymphocytes (TILs) are isolated from patients’ tumors. Once isolated, the TILs are then grown, expanded, and given back to the patients. On September 30, Lion Biotechnologies updated its Phase II metastatic melanoma results, and thus far the science is showing that it could become the new standard of care. The Phase II trial included 3 cohorts: 1 cohort treated with TILs alone and the other 2 cohorts treated with a combination of TILs and Total Body Irradiation.
The National Cancer Institute reported that the cohort using TILs alone demonstrated a 49 percent Objective Response. Objective Response is Partial Response plus Complete Response, with Partial Response defined as a reduction in tumor volume of more than 50 percent. Twelve percent of the 43 patients in this cohort showed a Complete Response and continue to live more than six years following treatment. The company plans to move the program into a Phase III clinical trial.
I'm glad I'm long this stock. Expect continued rise in the PPS. Many accomplishments with more in the works. Galena is positioning itself for a global presence. Teva partnership, Abstral acquisition, breast cancer treatment, new partnerships. Making waves!